Bladder cancer breakthrough? new combo aims to save bladders
NCT ID NCT07307456
First seen Jan 06, 2026 · Last updated Jun 14, 2026 · Updated 26 times
Summary
This study tests whether adding the immunotherapy drug toripalimab to standard BCG treatment can stop high-risk bladder cancer from returning after surgery. About 31 adults with aggressive non-muscle-invasive bladder cancer will receive the combination for 6 months. The goal is to see if more patients achieve a complete response and avoid needing bladder removal.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ChangHai Hospital
RECRUITINGShanghai, Shanghai Municipality, 200433, China
Conditions
Explore the condition pages connected to this study.